A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Guru Sonpavde, Benjamin Louis Maughan, Xiao X. Wei, Bradley Alexander McGregor, Kerry L. Kilbridge, Richard J. Lee, Evan Yu, Michael Thomas Schweizer, Robert B. Montgomery, Heather H. Cheng, Andrew Caleb Hsieh, Ruemu E. Birhiray, Nashat Y. Gabrail, John J. Nemunaitis, Arash Rezazadeh, Peter J. Van Veldhuizen, Nicholas J. Vogelzang, Christopher Ryan Heery, Petros Grivas
Institutions: Dana-Farber Cancer Institute, Huntsman Cancer Institute, Massachusetts General Hospital, University of Washington, Fred Hutch Cancer Center, Gabrail Cancer Center, University of Toledo, Norton Healthcare, University of Kansas Medical Center, Comprehensive Cancer Centers of Nevada, Bavarian Nordic (United States), Seattle Cancer Care Alliance
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2921689635